scholarly journals A potent multivalent vaccine for modulation of immune system in atherosclerosis: an in silico approach

2016 ◽  
Vol 5 (1) ◽  
pp. 50 ◽  
Author(s):  
Ahmad Karkhah ◽  
Jafar Amani
2021 ◽  
Vol 9 (2) ◽  
Author(s):  
Inggrid V. Gandu ◽  
Fona D. H. Budiarso ◽  
Billy J. Kepel ◽  
. Fatimawali ◽  
Aaltje Manampiring ◽  
...  

Abstract: Coronavirus Disease 2019 or COVID-19 is an infectious disease first identified in Wuhan, China in December 2019. Prevention of COVID-19 infection is an important thing to do in reducing the spread of this virus. Boosting the body's immune system can be done as a preventive measure, one of which is by consuming natural plants such as red guava. This study aims to determine the molecular docking of red guava (Psidium guajava L.) as a plant to prevent COVID-19. This was an in silico with computerized methods. The samples in this study were ascorbic acid and quercetin compounds in red guava plants obtained from the PubChem website. The results showed that the binding affinity of ascorbic acid is -5.4 and the binding affinity of quercetin is -7.6. Remdesivir which was used as a positive control had a binding affinity of -7.3. In conclusion, quercetin compounds have better results than ascorbic acid compounds and remdesivir.Keywords: COVID-19, red guava, molecular docking  Abstrak: Coronavirus Disease 2019 atau COVID-19 merupakan suatu penyakit menular yang pertama kali ditemukan di Wuhan, Tiongkok pada Desember 2019. Pencegahan infeksi COVID-19 merupakan hal yang penting untuk dilakukan dalam mengurangi penyebaran dari virus ini. Meningkatkan sistem imun tubuh dapat dilakukan sebagai tindakan pencegahan salah satunya dengan mengonsumsi tumbuhan-tumbuhan alami seperti jambu biji merah. Penelitian ini bertujuan untuk mengetahui molecular docking jambu biji merah (Psidium guajava L.) sebagai tanaman pencegah COVID-19. Jenis penelitian ialah in silico dengan metode komputerisasi. Sampel penelitian yaitu senyawa asam askorbat dan kuersetin pada tumbuhan jambu biji merah yang diperoleh dari website pubchem. Hasil penelitian mendapatkan binding affinity dari senyawa asam askorbat yaitu -5.4 dan binding affinity dari senyawa kuersetin yaitu -7.6. Remdesivir yang dijadikan sebagai kontrol positif mendapatkan hasil binding affinity yaitu -7.3. Simpulan penelitian ini ialah senyawa kuersetin memiliki hasil yang lebih baik daripada senyawa asam askorbat dan juga obat remdesivir.Kata kunci: COVID-19, jambu biji merah, molecular docking


2019 ◽  
Vol 20 (3) ◽  
pp. 214-225
Author(s):  
Mahbobeh Zamani-Babgohari ◽  
Kathleen L. Hefferon ◽  
Tsu Huang ◽  
Mounir G. AbouHaidar

Background: Nanoparticles derived from plant viruses possess fascinating structures, versatile functions and safe properties, rendering them valuable for a variety of applications. Papaya mosaic Virus-Like Particles (VLPs) are nanoparticles that contain a repetitive number of virus capsid proteins (PMV-CP) and are considered to be promising platforms for vaccine design. Previous studies have reported the antigenicity of PMV nanoparticles in mammalian systems. Materials and Methods: As experiments that concern vaccine development require careful design and can be time consuming, computational experiments are of particular importance. Therefore, prior to expressing PMV-CP in E. coli and producing nanoparticles, we performed an in silico analysis of the virus particles using software programs based on a series of sophisticated algorithms and modeling networks as useful tools for vaccine design. A computational study of PMV-CP in the context of the immune system reaction allowed us to clarify particle structure and other unknown features prior to their introduction in vitro. Results: The results illustrated that the produced nanoparticles can trigger an immune response in the absence of fusion with any foreign antigen. Conclusion: Based on the in silico analyses, the empty capsid protein was determined to be recognised by different B and T cells, as well as cells which carry MHC epitopes.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Shikha Tarang ◽  
Varun Kesherwani ◽  
Blake LaTendresse ◽  
Laramie Lindgren ◽  
Sonia M. Rocha-Sanchez ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Mariagrazia Belfiore ◽  
Marzio Pennisi ◽  
Giuseppina Aricò ◽  
Simone Ronsisvalle ◽  
Francesco Pappalardo

The revolutions in biotechnology and information technology have produced clinical data, which complement biological data. These data enable detailed descriptions of various healthy and diseased states and responses to therapies. For the investigation of the physiology and pathology of the immune responses, computer and mathematical models have been used in the last decades, enabling the representation of biological processes. In this modeling effort, a major issue is represented by the communication between models that work at cellular and molecular level, that is, multiscale representation. Here we sketch some attempts to model immune system dynamics at both levels.


mBio ◽  
2016 ◽  
Vol 7 (1) ◽  
Author(s):  
Macdonald Mahiti ◽  
Mako Toyoda ◽  
Xiaofei Jia ◽  
Xiaomei T. Kuang ◽  
Francis Mwimanzi ◽  
...  

ABSTRACTHIV-1 Nef binds to the cytoplasmic region of HLA-A and HLA-B and downregulates these molecules from the surface of virus-infected cells, thus evading immune detection by CD8+T cells. Polymorphic residues within the HLA cytoplasmic region may affect Nef’s downregulation activity. However, the effects of HLA polymorphisms on recognition by primary Nef isolates remain elusive, as do the specific Nef regions responsible for downregulation of HLA-A versus HLA-B. Here, we examined 46 Nef clones isolated from chronically HIV-1 subtype B-infected subjects for their ability to downregulate various HLA-A, HLA-B, and HLA-C molecules on the surface of virus-infected cells. Overall, HLA-B exhibited greater resistance to Nef-mediated downregulation than HLA-A, regardless of the cell type examined. As expected, no Nef clone downregulated HLA-C. Importantly, the differential abilities of patient-derived Nef clones to downregulate HLA-A and HLA-B correlated inversely with the sensitivities of HIV-infected target cells to recognition by effector cells expressing an HIV-1 Gag-specific T cell receptor. Nef codon function analysis implicated amino acid variation at position 202 (Nef-202) in differentially affecting the ability to downregulate HLA-A and HLA-B, an observation that was subsequently confirmed by experiments using Nef mutants constructed by site-directed mutagenesis. Thein silicoand mutagenesis analyses further suggested that Nef-202 may interact with the C-terminal Cys-Lys-Val residues of HLA-A, which are absent in HLA-B. Taken together, the results show that natural polymorphisms within Nef modulate its interaction with natural polymorphisms in the HLA cytoplasmic tails, thereby affecting the efficiency of HLA downregulation and consequent recognition by HIV-specific T cells. These results thus extend our understanding of this complex pathway of retroviral immune evasion.IMPORTANCERecognition of genetically diverse pathogens by the adaptive immune system represents a primary strategy for host defense; however, pathogens such as HIV-1 can evade these responses to achieve persistent infection. The HIV-1nefgene and theHLA class Ilocus rank among the most diverse genes of virus and host, respectively. The HIV-1 Nef protein interacts with the cytoplasmic region of HLA-A and HLA-B and downregulates these molecules to evade cellular immunity. By combining molecular, genetic, andin silicoanalyses, we demonstrate that patient-derived Nef clones downregulate HLA-A more effectively than HLA-B molecules. This in turn modulates the ability of HIV-specific T cells to recognize HIV-infected cells. We also identify a naturally polymorphic site at Nef codon 202 and HLA cytoplasmic motifs (GG314,315and CKV339–341) that contribute to differential HLA downregulation by Nef. Our results highlight new interactions between HIV-1 and the human immune system that may contribute to pathogenesis.


2020 ◽  
Vol 21 (S17) ◽  
Author(s):  
Giulia Russo ◽  
Giuseppe Sgroi ◽  
Giuseppe Alessandro Parasiliti Palumbo ◽  
Marzio Pennisi ◽  
Miguel A. Juarez ◽  
...  

Abstract Background In 2018, about 10 million people were found infected by tuberculosis, with approximately 1.2 million deaths worldwide. Despite these numbers have been relatively stable in recent years, tuberculosis is still considered one of the top 10 deadliest diseases worldwide. Over the years, Mycobacterium tuberculosis has developed a form of resistance to first-line tuberculosis treatments, specifically to isoniazid, leading to multi-drug-resistant tuberculosis. In this context, the EU and Indian DBT funded project STriTuVaD—In Silico Trial for Tuberculosis Vaccine Development—is supporting the identification of new interventional strategies against tuberculosis thanks to the use of Universal Immune System Simulator (UISS), a computational framework capable of predicting the immunity induced by specific drugs such as therapeutic vaccines and antibiotics. Results Here, we present how UISS accurately simulates tuberculosis dynamics and its interaction within the immune system, and how it predicts the efficacy of the combined action of isoniazid and RUTI vaccine in a specific digital population cohort. Specifically, we simulated two groups of 100 digital patients. The first group was treated with isoniazid only, while the second one was treated with the combination of RUTI vaccine and isoniazid, according to the dosage strategy described in the clinical trial design. UISS-TB shows to be in good agreement with clinical trial results suggesting that RUTI vaccine may favor a partial recover of infected lung tissue. Conclusions In silico trials innovations represent a powerful pipeline for the prediction of the effects of specific therapeutic strategies and related clinical outcomes. Here, we present a further step in UISS framework implementation. Specifically, we found that the simulated mechanism of action of RUTI and INH are in good alignment with the results coming from past clinical phase IIa trials.


Genes ◽  
2020 ◽  
Vol 11 (6) ◽  
pp. 615 ◽  
Author(s):  
Luigi Chiricosta ◽  
Agnese Gugliandolo ◽  
Placido Bramanti ◽  
Emanuela Mazzon

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system. It represents one of the main causes of neurological disability in young people. In MS, the autoimmune response is directed against myelin antigens but other possible bio-molecular markers are investigated. The aim of this work was, through an in silico study, the evaluation of the transcriptional modifications between healthy subjects and MS patients in six brain areas (corpus callosum, hippocampus, internal capsule, optic chiasm, frontal and parietal cortex) in order to identify genes representative of the disease. Our results show the upregulation of the Heat Shock Proteins (HSPs) HSPA1A, HSPA1B, HSPA7, HSPA6, HSPH1 and HSPA4L of the HSP70 family, among which HSPA1A and HSPA1B are upregulated in all the brain areas. HSP70s are molecular chaperones indispensable for protein folding, recently associated with immune system maintenance. The little overexpression of the HSPs protects the cells from stress but extreme upregulation can contribute to the MS pathogenesis. We also investigated the genes involved in the immune system that result in overall upregulation in the corpus callosum, hippocampus, internal capsule, optic chiasm and are absent in the cortex. Interestingly, the genes of the immune system and the HSP70s have comparable levels of expression.


2019 ◽  
Vol 20 (S6) ◽  
Author(s):  
Marzio Pennisi ◽  
Giulia Russo ◽  
Giuseppe Sgroi ◽  
Angela Bonaccorso ◽  
Giuseppe Alessandro Parasiliti Palumbo ◽  
...  

Abstract Background Tuberculosis (TB) represents a worldwide cause of mortality (it infects one third of the world’s population) affecting mostly developing countries, including India, and recently also developed ones due to the increased mobility of the world population and the evolution of different new bacterial strains capable to provoke multi-drug resistance phenomena. Currently, antitubercular drugs are unable to eradicate subpopulations of Mycobacterium tuberculosis (MTB) bacilli and therapeutic vaccinations have been postulated to overcome some of the critical issues related to the increase of drug-resistant forms and the difficult clinical and public health management of tuberculosis patients. The Horizon 2020 EC funded project “In Silico Trial for Tuberculosis Vaccine Development” (STriTuVaD) to support the identification of new therapeutic interventions against tuberculosis through novel in silico modelling of human immune responses to disease and vaccines, thereby drastically reduce the cost of clinical trials in this critical sector of public healthcare. Results We present the application of the Universal Immune System Simulator (UISS) computational modeling infrastructure as a disease model for TB. The model is capable to simulate the main features and dynamics of the immune system activities i.e., the artificial immunity induced by RUTI® vaccine, a polyantigenic liposomal therapeutic vaccine made of fragments of Mycobacterium tuberculosis cells (FCMtb). Based on the available data coming from phase II Clinical Trial in subjects with latent tuberculosis infection treated with RUTI® and isoniazid, we generated simulation scenarios through validated data in order to tune UISS accordingly to STriTuVaD objectives. The first case simulates the establishment of MTB latent chronic infection with some typical granuloma formation; the second scenario deals with a reactivation phase during latent chronic infection; the third represents the latent chronic disease infection scenario during RUTI® vaccine administration. Conclusions The application of this computational modeling strategy helpfully contributes to simulate those mechanisms involved in the early stages and in the progression of tuberculosis infection and to predict how specific therapeutical strategies will act in this scenario. In view of these results, UISS owns the capacity to open the door for a prompt integration of in silico methods within the pipeline of clinical trials, supporting and guiding the testing of treatments in patients affected by tuberculosis.


Sign in / Sign up

Export Citation Format

Share Document